Atea Pharmaceuticals, a Phase 2 biotech developing therapies for COVID-19 and other viral diseases, raised $300 million by offering 12.5 million shares at $24, the high end of the range of $22 to $24 according to an S-1MEF filed with the SEC. The company originally filed to offer 11.0 million shares.
Atea Pharmaceuticals plans to list on the Nasdaq under the symbol AVIR. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as lead managers on the deal.
Thursday, October 29, 2020
COVID-19 viral biotech Atea Pharmaceuticals prices upsized IPO at $24 high end
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.